SecBot SecBot
PRESS-RELEASE ·Filed Jun 15, 2026

AXSM

Axsome Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

The presentations are routine scientific updates with no regulatory or financial catalysts. Monitor for future AXS-12 NDA filing timing and any solriamfetol label expansion updates as material next steps, but this filing provides no new trade-triggering information.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$253.40
T+0 close · Jun 15, 2026 · via day close
Latest settled
−16.88%
T+60 · $210.63
Vs SPY
−17.88%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 15 $253.40entry
  2. T+1 · 5mo ago −0.59%α +0.01% · $251.91
  3. T+5 · 5mo ago −2.19%α −0.81% · $247.85
  4. T+20 · 4mo ago −9.91%α −9.16% · $228.28
  5. T+60 · 2mo ago −16.88%α −17.88% · $210.63
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Axsome Therapeutics presented new data on AXS-12 and solriamfetol at SLEEP 2026, including cognitive/functional outcomes from the Phase 3 ENCORE trial and post-hoc composite endpoint analyses. The presentations do not contain new regulatory milestones, financial results, or concrete catalysts, this is a routine scientific conference update without material new information for the stock.

Key Facts

  • Presented Phase 3 ENCORE trial data for AXS-12 in narcolepsy with cataplexy at SLEEP 2026
  • Presented post-hoc composite endpoint analysis of solriamfetol Phase 3 trials in narcolepsy and OSA
  • Presented subgroup analysis from CRESCENDO survey on residual cataplexy symptom burden
  • No new approvals, regulatory submissions, or financial guidance were announced
  • Conference runs June 14-17, 2026 in Baltimore

Financial Impact

No financial figures disclosed; routine scientific conference presentations with no immediate revenue or cost impact

Risk Factors

  • AXS-12 and solriamfetol pipeline progress remains subject to clinical and regulatory risks
  • No new efficacy or safety signals that change the probability of approval

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3311661

Track record

26 reports on AXSM

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 2, 202614d ago 8-K Bullish 6/10 No price data
  2. Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
  3. Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
  4. Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
  5. Aug 10, 202614w ago 8-K Neutral 6/10 No price data
  6. Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
  7. Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
  8. Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
  9. Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
  10. Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 7h 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026